The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer
Open accessAbstract
TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer. Here, we explored the role of TMPRSS2-ERG gene fusion product using in vitro and in vivo model systems. Transgenic mice expressing the ERG gene fusion product under androgen-regulation develop mouse prostatic intraepithelial neoplasia (PIN), a precursor lesion of prostate cancer. Introduction of the ERG gene fusion product into primary or immortalized benign prostate epithelial cells induced an invasion-associated transcriptional program but did not increase cellular proliferation or anchorage-independent growth. These results suggest that TMPRSS2-ERG may not be sufficient for transformation in the absence of secondary molecular lesions. Transcriptional profiling of ERG knockdown in the TMPPRSS2-ERG-positive prostate cancer cell line VCaP revealed decreased expression of genes over-expressed in prostate cancer versus PIN and genes overexpressed in ETS-positive versus -negative prostate cancers in addition to inhibiting invasion. ERG knockdown in VCaP cells also induced a transcriptional program consistent with prostate differentiation. Importantly, VCaP cells and benign prostate cells overexpressing ERG directly engage components of the plasminogen activation pathway to mediate cellular invasion, potentially representing a downstream ETS target susceptible to therapeutic intervention. Our results support previous work suggesting that TMPRSS2-ERG fusions mediate invasion, consistent with the defining histologic distinction between PIN and prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Self-citationGene expression profiling identifies clinically relevant subtypes of prostate cancer
Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., Ferrari, M., Egevad, L., Rayford, W., Bergerheim, U., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304146101 · Cited by 1,292
Integrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922
Self-citationDistinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844
Self-citationMyc-driven murine prostate cancer shares molecular features with human prostate tumors
Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., Thomas, G. V., & Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00197-1 · Cited by 816
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
Demichelis, F., Fall, K., Perner, S., Andrén, O., Schmidt, F., Setlur, S. R., Hoshida, Y., Mosquera, J.-M., Pawitan, Y., Lee, C., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210237 · Cited by 645
Self-citationShappell, S. B., Thomas, G. V., Roberts, R. L., Herbert, R., Ittmann, M. M., Rubin, M. A., Humphrey, P. A., Sundberg, J. P., Rozengurt, N., Barrios, R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0946 · Cited by 598
Self-citationProstate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2.
Lin, B., Ferguson, C., White, J. T., Wang, S., Vessella, R. L., True, L. D., Hood, L., & Nelson, P. S. (1999) · PubMed · Cited by 531
TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer
Perner, S., Demichelis, F., Beroukhim, R., Schmidt, F. H., Mosquera, J.-M., Setlur, S., Tchinda, J., Tomlins, S. A., Hofer, M. D., Pienta, K. G., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1482 · Cited by 502
Self-citationPten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse
Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., & P Pandolfi, P. (2001) · Nature Genetics · doi:10.1038/84879 · Cited by 498
Gene expression profiling predicts clinical outcome of prostate cancer
Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M., & Gerald, W. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20032 · Cited by 479
Pathological and molecular aspects of prostate cancer
DeMarzo, A. M., Nelson, W. G., Isaacs, W. B., & Epstein, J. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12779-1 · Cited by 472
TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer
Tomlins, S. A., Mehra, R., Rhodes, D. R., Smith, L. R., Roulston, D., Helgeson, B. E., Cao, X., Wei, J. T., Rubin, M. A., Shah, R. B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0168 · Cited by 469
Self-citationTMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion
Perner, S., Mosquera, J.-M., Demichelis, F., Hofer, M. D., Paris, P. L., Simko, J., Collins, C., Bismar, T. A., Chinnaiyan, A. M., De Marzo, A. M., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213424.38503.aa · Cited by 426
Self-citationWang, J., Cai, Y., Ren, C., & Ittmann, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1966 · Cited by 404
Amiloride selectively inhibits the urokinase‐type plasminogen activator
Vassalli, J.-D., & Belin, D. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80039-x · Cited by 380
Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis
Kim, M. J., Cardiff, R. D., Desai, N., Banach-Petrosky, W. A., Parsons, R., Shen, M. M., & Abate-Shen, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042688999 · Cited by 338
VCaP, a cell-based model system of human prostate cancer.
Korenchuk, S., Lehr, J. E., McLean, L. L., Lee, Y.-G., Whitney, S. C., Vessella, R. L., Lin, D. L., & Pienta, K. J. (2001) · PubMed · Cited by 323
Vanaja, D. K., Cheville, J. C., Iturria, S., & Young, C. Y. F. (2003) · PubMed · Cited by 305
Mehra, R., Tomlins, S. A., Shen, R., Nadeem, O., Wang, L., Wei, J. T., Pienta, K. J., Ghosh, D., Rubin, M. A., Chinnaiyan, A. M., et al. (2007) · Modern Pathology · doi:10.1038/modpathol.3800769 · Cited by 303
Self-citationCharacterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer
Helgeson, B. E., Tomlins, S. A., Shah, N., Laxman, B., Cao, Q., Prensner, J. R., Cao, X., Singla, N., Montie, J. E., Varambally, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5352 · Cited by 276
Self-citationc-Myc target gene specificity is determined by a post-DNAbinding mechanism
Boyd, K. E., Wells, J., Gutman, J., Bartley, S. M., & Farnham, P. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13887 · Cited by 276
Matrix metalloproteinases: roles in cancer and metastasis
Fingleton, B. (2006) · Frontiers in Bioscience · doi:10.2741/1811 · Cited by 271
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate
Clark, J., Merson, S., Jhavar, S., Flohr, P., Edwards, S., Foster, C. S., Eeles, R., Martin, F. L., Phillips, D. H., Crundwell, M., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210070 · Cited by 271
Cerveira, N., Ribeiro, F. R., Peixoto, A., Costa, V., Henrique, R., Jerönimo, C., & Teixeira, M. R. (2006) · Neoplasia · doi:10.1593/neo.06427 · Cited by 258
Dechow, T. N., Pedranzini, L., Leitch, A., Leslie, K., Gerald, W. L., Linkov, I., & Bromberg, J. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404100101 · Cited by 254
Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia
Abdulkadir, S. A., Magee, J. A., Peters, T. J., Kaleem, Z., Naughton, C. K., Humphrey, P. A., & Milbrandt, J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.5.1495-1503.2002 · Cited by 254
Iljin, K., Wolf, M., Edgren, H., Gupta, S., Kilpinen, S., Skotheim, R. I., Peltola, M., Smit, F., Verhaegh, G., Schalken, J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1986 · Cited by 241
Hermans, K. G., van Marion, R., van Dekken, H., Jenster, G., van Weerden, W. M., & Trapman, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1871 · Cited by 240
Evolution of the Androgen Receptor Pathway during Progression of Prostate Cancer
Hendriksen, P. J. M., Dits, N. F. J., Kokame, K., Veldhoven, A., van Weerden, W. M., Bangma, C. H., Trapman, J., & Jenster, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3082 · Cited by 226
A DNA microarray survey of gene expression in normal human tissues
Shyamsundar, R., Kim, Y. H., Higgins, J. P., Montgomery, K., Jorden, M., Sethuraman, A., van de Rijn, M., Botstein, D., Brown, P. O., & Pollack, J. R. (2005) · Genome Biology · doi:10.1186/gb-2005-6-3-r22 · Cited by 226
Zhang, J., Thomas, T. Z., Kasper, S., & Matusik, R. J. (2000) · Endocrinology · doi:10.1210/endo.141.12.7837 · Cited by 219 · cited 2×
“2, C-terminal FLAG-tagged) under the control of the modified probasin promoter (ARR2Pb-ERG ) (Figure 1 a ), which drives androgen-regulated transgene expression exclusively Neoplasia Vol. 10, No. 2, 2008 TMPRSS2 – ERGin Prostate Cancer Tomlins et al. in the prostate [23,24].”
Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer
Soller, M. J., Isaksson, M., Elfving, P., Soller, W., Lundgren, R., & Panagopoulos, I. (2006) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20329 · Cited by 195
Yoshimoto, M., Joshua, A. M., Chilton-MacNeill, S., Bayani, J., Selvarajah, S., Evans, A. J., Zielenska, M., & Squire, J. A. (2006) · Neoplasia · doi:10.1593/neo.06283 · Cited by 185
Rajput, A. B., Miller, M. A., De Luca, A., Boyd, N., Leung, S., Hurtado-Coll, A., Fazli, L., Jones, E. C., Palmer, J. B., Gleave, M. E., et al. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.043810 · Cited by 175
Nam, R. K., Sugar, L., Wang, Z., Yang, W., Kitching, R., Klotz, L. H., Venkateswaran, V., Narod, S. A., & Seth, A. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.1.3489 · Cited by 164
Mertz, K. D., Setlur, S. R., Dhanasekaran, S. M., Demichelis, F., Perner, S., Tomlins, S. A., Tchinda, J., Laxman, B., Vessella, R. L., Beroukhimt, R., et al. (2007) · Neoplasia · doi:10.1593/neo.07103 · Cited by 149
Self-citationStegmaier, K., Wong, J. S., Ross, K. N., Chow, K. T., Peck, D., Wright, R. D., Lessnick, S. L., Kung, A. L., & Golub, T. R. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040122 · Cited by 145
Molecular Concepts Analysis Links Tumors, Pathways, Mechanisms, and Drugs
Rhodes, D. R., Sundaram, S. K., Tomlins, S. A., Mahavisno, V., Kasper, N. M., Varambally, R., Barrette, T. R., Ghosh, D., Varambally, S., & Chinnaiyan, A. M. (2007) · Neoplasia · doi:10.1593/neo.07292 · Cited by 139
Self-citationLapointe, J., Kim, Y. H., Miller, M. A., Li, C., Kaygusuz, G., van de Rijn, M., Huntsman, D. D., Brooks, J. D., & Pollack, J. R. (2007) · Modern Pathology · doi:10.1038/modpathol.3800759 · Cited by 134
The Ets transcription factors of the PEA3 group: Transcriptional regulators in metastasis
de Launoit, Y., Baert, J., Chotteau‐Lelièvre, A., Monté, D., Coutte, L., Mauën, S., Firlej, V., Degerny, C., & Verreman, K. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.02.002 · Cited by 129
Plasminogen Activator Inhibitor-1
Gils, A., & Declerck, P. J. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364595 · Cited by 129
Winnes, M., Lissbrant, E., Damber, J., et al. (2007) · Oncology Reports · doi:10.3892/or.17.5.1033 · Cited by 117
Henshall, S. M., Afar, D., Rasiah, K., Horvath, L. G., Gish, K., Caras, I. W., Ramakrishnan, V., Wong, M. H. L., Jeffry, U. B., Kench, J. G., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206797 · Cited by 115
Laufs, S., Schumacher, J., & Allgayer, H. (2006) · Cell Cycle · doi:10.4161/cc.5.16.2994 · Cited by 93
Transcriptomes of human prostate cells
Oudes, A. J., Campbell, D., Sorensen, C. M., Walashek, L. S., True, L. D., & Liu, A. Y. C. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-92 · Cited by 72
INTEGRATIVE BIOLOGY OF PROSTATE CANCER PROGRESSION
Tomlins, S. A., Rubin, M. A., & Chinnaiyan, A. M. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100047 · Cited by 66
Self-citation
Cited by
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Metadata
- Authors
- Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., Cao, Q., Prensner, J. R., Rubin, M. A., Shah, R. B., Mehra, R., & Chinnaiyan, A. M.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 10
- Issue
- 2
- Pages
- 177-IN9
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W2082462837
- Cited by
- 690
- References
- 47
- FWCI
- 39.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.